NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-19-062 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-236 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services.
Funding Opportunity PAR-19-235 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP.
Funding Opportunity PAR-19-234 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.
Notice NOT-EY-19-022 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-026 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-037 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage the development of vaccines and other approaches for the prevention of Lyme disease and/or other tick-borne diseases.
Notice NOT-EY-19-023 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-021 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-020 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-232 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for support of mature structural biology resources at synchrotron facilities. Mature refers to the techniques made available at the resource beamlines: they must be well-established, requiring no significant novel technology development in order to provide utility to the communities they serve or to maintain them as state-of-the-art beamlines. This funding opportunity is limited to resources whose operations recently have been or currently are being supported by NIGMS funding. The intent is to provide access to X-ray beamlines for structural biology research. It is expected that the facility will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support
Funding Opportunity RFA-DA-19-038 from the NIH Guide for Grants and Contracts. Along with RFA-DA-19-037, which will support the generation of single cell datasets for one or more brain regions relevant to opioid use disorder and persistent HIV infection, a data coordination/analysis/outreach center (RFA-DA-19-038) will be established to make NIDA-funded single cell data and other molecular HIV/SUD data FAIR (Findable, Accessible, Interoperable, and Reusable). Harmonized single cell HIV/SUD data sets will enable immediate data mining by the scientific community for HIV and/or SUD biomarkers and potential pathways for therapeutic intervention. It will also enable future mining of these data sets as new and improved data science and information technology approaches are developed, maximizing NIDAs original investment in the data generating activities.
Funding Opportunity RFA-DA-19-037 from the NIH Guide for Grants and Contracts. To support generation of single cell datasets for one or more brain regions relevant to opioid use disorder and persistent HIV infection. If fully successful, this project will generate 1. A cellular parts list for selected NIDA-relevant brain regions, 2. Reveal how cell types within these brain regions differ from one another with respect to gene expression, 3. Reveal how cell types within these brain regions are altered by chronic opioid exposure providing potential novel therapeutic targets for opioid addiction, 4. Reveal how HIV infection in the CNS influences single cells, providing potential targets for improving HIV neurobiological sequelae, and 5. Uncover potential synergistic effects of chronic opioid exposure and HIV infection in the CNS.
Notice NOT-GM-19-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-036 from the NIH Guide for Grants and Contracts. The objective of this FOA is to advance non-sputum-based tuberculosis (TB) diagnostics for use in HIV-1 infected and HIV-1 exposed uninfected children (HEU) for improved, simplified, rapid and decentralized diagnosis of TB disease. This opportunity will support discovery and validation of novel biomarkers useful for TB diagnosis or the development/optimization and early validation of novel TB diagnostic technologies.
Funding Opportunity PAR-19-231 from the NIH Guide for Grants and Contracts. The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.
Notice NOT-CA-19-038 from the NIH Guide for Grants and Contracts
Notice NOT-OH-19-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-230 from the NIH Guide for Grants and Contracts. This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia.